Vanda Pharmaceuticals Secures FDA Rare Pediatric Disease Designation for Antisense Oligonucleotide Therapy VCA-894A in CMT2S

Vanda Pharmaceuticals Inc.查看公司主页 announced on July 7, 2026 that the U.S. Food and Drug Administration has granted Rare Pediatric Disease Designation to VCA-894A查看药品详情, the company's investigational antisense oligonucleotide (ASO) therapy for Charcot-Marie-Tooth disease, axonal, type 2S (CMT2S). The designation was awarded jointly by the FDA's Office of Orphan Products Development and Office of Pediatric Therapeutics, underscoring the significant unmet medical need in this devastating pediatric neurological condition.

CMT2S is a rare inherited neurological disorder characterized by chronic progressive degeneration of peripheral nerves, resulting in sensory and motor impairment that can lead to severe disability, including loss of ambulation. The disease has an estimated prevalence of less than 1 in 1,000,000 worldwide. The FDA determined that CMT2S qualifies as a rare pediatric disease because it is a serious or life-threatening condition whose manifestations primarily affect individuals from birth through 18 years of age and meets the statutory definition of a rare disease.

"CMT2S is a devastating inherited neuropathy for which patients and families have limited treatment options," said Mihael H. Polymeropoulos, M.D., President, Chief Executive Officer and Chairman of Vanda. "The FDA's Rare Pediatric Disease Designation recognizes the significant unmet medical need in this patient population and supports our efforts to develop a potentially transformative therapy for patients affected by this rare disease."

Mechanism and Personalized Approach of VCA-894A查看药品详情

VCA-894A查看药品详情 is a 2'-O-methoxyethyl (MOE) phosphorothioate oligonucleotide sodium salt that specifically targets a cryptic splice site variant within the IGHMBP2 (搜索)搜索该靶点 gene, which is the causative mutation for CMT2S. The therapeutic target is a unique variant of CMT2S not yet observed in any other patient, reflecting the highly personalized nature of this investigational therapy. The severity and clinical presentations of CMT2S are influenced by the diverse genetic variants associated with CMT disease, making this targeted approach particularly relevant.

VCA-894A查看药品详情 is being developed for a patient who was first diagnosed at an early age with this rare subtype of CMT. The ASO platform may have broad applicability in addressing a number of disorders, from nervous system treatments to systemic treatments, according to Vanda.

Regulatory Implications and Priority Review Voucher Potential

The Rare Pediatric Disease Designation is intended to encourage the development of new therapies for serious or life-threatening rare diseases that primarily affect children. Under the Rare Pediatric Disease Priority Review Voucher program, a sponsor whose product ultimately meets all statutory requirements may become eligible to receive a priority review voucher upon approval of a qualifying marketing application. Eligibility for any future priority review voucher will be determined at the time of a marketing application's review and approval.

Vanda stated it is advancing development of its investigational therapy for CMT2S and will continue to work closely with the FDA regarding the development program. The company noted that forward-looking statements regarding the estimated prevalence of CMT2S, the therapeutic potential of VCA-894A查看药品详情, and eligibility for a priority review voucher are subject to risks and uncertainties, and no assurance can be given that anticipated results or developments will be realized.